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Abstract
Purpose—To assess the optimal age at which a one-time HIV screen should begin for 
adolescents and young adults (AYA) in the United States without identified HIV risk factors, 
incorporating clinical impact, costs, and cost-effectiveness.
Methods—We simulated HIV-uninfected 12-year-olds in the US without identified risk factors 
who faced age-specific risks of HIV infection (0.6–71.3/100,000PY). We modeled a one-time 
screen ($36) at age 15, 18, 21, 25, or 30, each in addition to current US screening practices (30% 
screened by age 24). Outcomes included retention in care, virologic suppression, life expectancy, 
lifetime costs and incremental cost-effectiveness ratios in $/year-of-life saved (YLS) from the 
healthcare system perspective. In sensitivity analyses, we varied HIV incidence, screening and 
linkage rates, and costs.
Results—All one-time screens detected a small proportion of lifetime infections (0.1–10.3%). 
Compared to current US screening practices, a screen at age 25 led to the most favorable care 
continuum outcomes at age 25: proportion diagnosed (77% vs. 51%), linked to care (71% vs. 
51%), retained in care (68% vs. 44%) and virologically suppressed (49% vs. 32%). Compared to 
the next most effective screen, a screen at age 25 provided the greatest clinical benefit, and was 
cost-effective ($96,000/YLS) by US standards (<$100,000/YLS).
Conclusions—For US AYA without identified risk factors, a one-time routine HIV screen at age 
25, after the peak of incidence, would optimize clinical outcomes and be cost-effective compared 
to current US screening practices. Focusing screening on AYA ages 18 or younger is a less 
efficient use of a one-time screen among AYA than screening at a later age.
Keywords
Human immunodeficiency virus; HIV screening; HIV testing; Adolescence; Young adults
The US Centers for Disease Control and Prevention (CDC) estimate that 22% of new HIV 
diagnoses occur in adolescents and young adults (AYA) aged 13–24 years, and that nearly 
61,000 AYA are now living with HIV in the US [1, 2]. In 2006, CDC recommended routine 
HIV screening at least once between the ages of 13–64, regardless of risk factors [3]. 
However, HIV screening rates among AYA remain low: 12% of US high school students 
reported ever being screened in 2005, increasing only to 13% by 2012 [4]. Among older 
youth aged 18–24, the proportion who had ever been screened declined over a similar 
period, from 37% reported in 2000 to 30% in 2010.
Of all AYA aged 13–24 living with HIV, 51% are estimated to be unaware of their HIV 
status, substantially higher than the 13% of HIV-infected US adults estimated to be unaware 
of their status [2]. People unaware of their HIV infection miss opportunities for treatment 
and improved individual health, as well as contribute disproportionately to HIV transmission 
[5]. CDC recommends that people at high risk for HIV infection, including people who have 
had sex with more than one partner since their last HIV screen, sexually active men who 
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have sex with men, and injection drug users, be rescreened at least annually [3]. For youth 
without identified risk factors, however, uptake of CDC guidelines for routine screening may 
be limited by differing recommendations among national professional organizations, as well 
as lack of evidence that 13 is the optimal age at which to initiate HIV screening in AYA [6, 
7]. While many youth with unknown risk factors may be at higher risk of HIV infection than 
either they or their healthcare providers perceive [8], we hypothesized that offering a one-
time screen at a younger age may cause harm by missing infections that occur later. 
Additionally, offering an HIV test to a 13-year-old without identified risk factors might take 
the place of potentially higher priority health considerations such as catch-up immunizations 
or assessing safety and counseling on injury prevention [9]. Our objective was to identify the 
age at which the CDC recommendation for one-time HIV screening should begin. We thus 
assessed the clinical impact, cost and cost-effectiveness of one-time HIV screening strategies 
for AYA aged 13–24 in the US without identified HIV risk factors.
METHODS
Analytic overview
We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) 
microsimulation model to evaluate the cost-effectiveness of alternative strategies for routine 
one-time HIV screening in youth aged 13–24, in addition to current HIV screening and 
testing practices in the US (13% ever screened by age 18, and 30% by age 24) [4]. We 
simulated HIV-uninfected 12-year-olds without identified risk factors (Table 1). We modeled 
5 screening strategies: a onetime screen at age 15, 18, 21, 25 or 30 years; each one-time 
screening strategy was performed in addition to current practice. Screens at age 25 and 30 
were included to determine the value of screening after the AYA period. Model outcomes 
included CD4 cell count at diagnosis, life expectancy and HIV-related lifetime costs from 
the healthcare system perspective. In the base case, life expectancy was not quality-adjusted 
due to limited data among AYA [22]. To compare the marginal cost for an additional unit of 
health benefit when choosing between these different strategies, we report incremental cost-
effectiveness ratios (ICERs) [23]. We calculated ICERs for each strategy compared to the 
next most costly alternative (Δ cost/Δ life expectancy), using outcomes for HIV-infected and 
HIV-uninfected people. Results were discounted at 3%/year to convert future costs and 
health outcomes [23]. We defined a strategy as “cost-effective” if its ICER fell below a 
willingness-to-pay threshold of $100,000/year-of-life saved (YLS) [24]; we examine a range 
of ICER thresholds in sensitivity analyses.
Model structure, population, and data parameters
The CEPAC model is a patient-level simulation model of HIV infection, screening, disease 
progression, and treatment calibrated to clinical data with and without antiretroviral therapy 
(ART) in the US (http://web2.research.partners.org/cepac) [25]. Youth enter the model at age 
12 without HIV infection, and are simulated through their lifetimes until death.
HIV incidence and diagnosis—Simulated patients face monthly risks of HIV infection, 
based on age-stratified incidence rates (Table 1 and online Appendix Table A1). For patients 
who become infected, diagnosis can occur via current practice of HIV detection (e.g. HIV 
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screening and testing already occurring in healthcare settings), or testing after presenting to 
care with an opportunistic infection (OI) or the one-time HIV screening program.
The model includes age-stratified monthly probabilities of detection under current practice 
HIV screening. Current practice screening rates were derived from Youth Risk Behavior 
Survey (YRBS) data for 13- to 17-year-olds (% ever tested) and the National Health 
Interview Survey (NHIS) for people >18 years (% tested within 12 months) (Table 1) [4]. 
We used National HIV Surveillance System (NHSS) data on stage of disease at HIV 
diagnosis during 2013, stratified by age, to calibrate these rates (Appendix Table A2) [11].
In addition to current practice, a one-time HIV screen was offered to both infected and 
uninfected patients (Table 1). In the base case analysis, for all one-time screening strategies, 
we assumed an 80.0% combined probability of being offered and accepting screening, 
97.0% result return, 75.6% linkage to care and ART provision after a positive screen (based 
on data for AYA aged 13–24 when available), as well as screening costs of $35.92 per screen 
plus an additional $72.23 per completed reactive screen [13–15, 25, 26]. HIV screening was 
modeled as a fourth generation HIV immunoassay per CDC recommendations.
Disease progression and treatment—In the month of HIV infection, simulated 
patients are assigned a CD4 cell count and HIV RNA level from defined distributions (Table 
1 and Appendix Table A1). ART is initiated in all patients who link to care, per US 
guidelines [27]. After ART initiation, simulated patients face a probability of virologic 
suppression and a resulting increase in CD4 cell count stratified by adherence [28]. Patients 
on suppressive ART experience a monthly probability of virologic failure after 48 weeks, 
also stratified by adherence [21, 29]. Monthly risks of OIs and mortality are determined by 
age, current CD4 cell count, and prior disease history. The model tallies time in each health 
state and associated costs, including clinical care, laboratory screening, and medications [25, 
28].
HIV care continuum—The model also generates HIV care continuum outcomes 
(proportions HIV-diagnosed, linked to care, retained in care, and virologically suppressed). 
Monthly risks of becoming lost to follow-up and returning to care reflect movement within 
the care continuum (Table 1).
Sensitivity analyses and additional analyses
In sensitivity analyses, we first varied HIV incidence from 5- to 100-fold the base case 
inputs. The 5-fold increase approximated 2013 rates of new diagnoses reported among 
African American males (Appendix Figure A1) [11, 12]. We next shifted the age distribution 
of HIV incidence, ranging peak age from 15–28 (Appendix Figure A2), and varied rates of 
current practice HIV screening from 0.5- to 2-fold the base case. We also varied parameters 
of the HIV screening program, CD4 cell count at infection, loss to follow-up, virologic 
suppression, and HIV-related healthcare costs. We examined HIV screening and HIV care 
costs up to 5-fold the base case to understand where the ICER threshold was crossed. In 
multi-way sensitivity analyses, we varied the most influential of these parameters 
simultaneously, including costs of HIV screening and HIV care, and linkage.
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Because of limited data in AYA, we excluded quality-of-life adjustments in the primary 
analysis. In sensitivity analysis, we used quality-of-life weights from adults, generating 
ICERs in $/quality-adjusted life-year ($/QALY), a more common unit for ICERs. We also 
calculated the proportion of one generation of HIV transmissions/100 person-years that 
would be averted by each strategy to estimate the impact on the optimal age for a one-time 
screen. The likelihood that a person will transmit HIV to others is modeled as a function of 
the HIV RNA level; HIV RNA-stratified transmission rates ranged from 0.16–9.03 
transmissions/100 person-years, with higher rates for those within three months of infection 
and for those with advanced infection (Appendix Table A1). Further, we examined one-time 
screens at every age between 13–35 years to determine whether clinical and cost differences 
at similar ages were meaningful.
Base case results are reported according to cost-effectiveness convention, in order of 
increasing costs; ICERs are calculated comparing each strategy to the next most costly 
strategy after eliminating “dominated” strategies, which are strategies that are either more 
costly or less cost-effective than other strategies that produce greater benefits [23]. For 
sensitivity analyses, we report ICERs comparing the most effective strategy to current 
practice because of variation in the comparator strategies when calculating ICERs. Details of 
additional model parameters can be found online in the appendix.
RESULTS
Base case results: clinical outcomes
Among 12-year-olds in the US without identified HIV risk factors, the projected number of 
new HIV infections peaked at age 24, although more than 75% of lifetime infections were 
projected to occur afterwards (mean age: 37.3 years [SD 16.9 years] (Appendix Figure A1). 
Among AYA who became HIV-infected at any point in their lifetime, current practice led to 
a projected mean CD4 cell count at diagnosis of 324 cells/μL and an undiscounted life 
expectancy from age 12 of 585.05 months (48.75 years) (Table 2).
When projected for the entire cohort (including those becoming and never becoming HIV-
infected), life expectancy from age 12 was 810.90 months (67.58 years) (344.49 months 
[28.71 years] discounted).
Any evaluated one-time screen in addition to current practice increased projected CD4 cell 
count at diagnosis and life expectancy among HIV-infected people. Of the one-time 
screening strategies, a screen at age 25 led to the highest projected mean CD4 cell count at 
diagnosis (345 cells/μL) and the greatest gains in undiscounted HIV-infected life expectancy 
from age 12 (589.82 months, an increase of 4.8 months over current practice). The impact of 
any one-time screen on discounted life expectancy for the total population (HIV-infected and 
HIV-uninfected people) was very small (current practice: 810.90 months [344.49 months 
discounted]; additional screen at age 25: 810.97 months [344.52 months discounted]).
HIV detection
All one-time screening strategies identified a small proportion of total lifetime HIV 
infections (0.1–10.3%) (Figure 1a), because most infections occurred after age 25 
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(Appendix Figure A1). Screen at age 25 provided the lowest proportions never diagnosed 
(10.6%) and diagnosed via OI (34.8%) (Appendix Figure A3a). Even a perfect screen at age 
25 (100% test offer and acceptance, result return, and linkage) would detect only 13% of 
lifetime infections. When limited to people infected before age 25, one-time screening 
strategies identified a larger proportion of HIV infections (0.4–33.8%), and results were still 
optimized with screen at age 25 (Figure 1b, Appendix Figure A3b).
HIV care continuum outcomes at age 25 years and 11 months
Assessing outcomes at age 25 years and 11 months, screen at age 25 led to the most 
favorable care continuum outcomes, with 77.3% diagnosed, 70.8% linked to care, 61.5% 
retained in care, and 51.4% virologically suppressed (Figure 2, Appendix Figure A4).
Base case results: cost and cost-effectiveness
Current practice led to the lowest projected HIV-related healthcare costs for the cohort, with 
lifetime discounted costs of $2,860/person (Table 2, Appendix Figure A5). Lifetime HIV-
related healthcare costs were greatest for the strategy with the most favorable clinical 
outcomes (screen at age 25: $3,000/person). In cost-effectiveness analyses, screens at age 
15, 18 or 21 were dominated. The ICER of screen at age 30 compared to current practice 
was $62,500/YLS; the ICER of screen at age 25 compared to screen at age 30 was $96,000/
YLS.
Sensitivity analyses
The ICER of screen at age 25 compared to current practice was most sensitive to linkage to 
care, increasing HIV screen costs, and HIV healthcare costs (Figure 3). A one-time screen at 
age 25 optimized clinical outcomes over wide ranges in loss to follow-up, current practice 
screening, screen offer and acceptance, result return, screen sensitivity and specificity, CD4 
cell count at infection and absolute increases in HIV incidence. If the one-time HIV 
screening program characteristics were much worse, the benefits of one-time screening 
strategies at any age were attenuated, and the cost-effectiveness ratios increased, but the 
optimal age for screening AYA remained after the peak of incidence. Cost-effectiveness 
outcomes improved with one-time screening at younger ages if the peak of HIV incidence 
was earlier and, conversely, with onetime screening at older ages if the peak of incidence 
was later (Appendix Table A3). Additional two-way sensitivity analyses of the most 
influential parameters are reported in the appendix (Appendix Figure A6).
Additional analyses
In the base case, using adult quality-of-life weights for AYA increased the ICER of screen at 
25 compared to screen at age 30 to $115,900/QALY. The greatest reduction in HIV 
transmissions/100 person-years occurred with a screen at age 25 (3.8%) compared to current 
practice (range 0.05–3.8% for any one-time screen) (Figure A7). Evaluation of one-time 
screens between ages 13–35 revealed negligible differences in outcomes between specific 
consecutive yearly ages, and the policy conclusion favoring a test in the mid-20s was 
unchanged.
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DISCUSSION
Our objective was to assess whether the CDC recommendation for one-time HIV screening 
between the ages of 13–64 should begin at age 13. We determined the value of one-time 
HIV screening, in addition to current screening practices, in AYA aged 13–24 without 
identified risk factors for HIV infection in the US. We had three principal findings. First, 
although an additional one-time screen at any age between 15–30 led to important gains in 
HIV diagnosis rates and life expectancy for HIV-infected people, a screen at age 25 provided 
the most favorable clinical outcomes and the best value for money. Compared to current 
practice, an additional one-time screen at age 25 led to a substantial gain in HIV-infected life 
expectancy of 4.8 months and was cost-effective in the US (ICER compared to a screen at 
age 30: $96,000/YLS) [23, 24, 30]. These results align with other analyses which have found 
HIV screening to be cost-effective in the US in all but the lowest-risk populations [25, 31, 
32]. CDC recommends screening for HIV infection at least once for all people aged 13–64 
years [3]. Our results suggest that if a one-time screen is offered to AYA without identified 
risk factors, it would provide greater clinical benefit and economic value if offered later, in 
the mid-20s, than if offered in early adolescence. In this analysis, a screen at age 18 or 21 
was only superior to a screen at age 25 if HIV incidence peaked at earlier ages. Diagnoses of 
new HIV infections among persons aged 13–29 years peaked between ages 22–25 from 
2009–2013 [11]. While the timing of peak HIV incidence among persons aged 13–29 is 
unknown, it is unlikely that the population peak of HIV incidence in youth without identified 
risk factors occurs before age 18.
Second, while gains in life expectancy and the number of AYA detected by the one-time 
screen were small (because most infections occurred after age 24), a screen at age 25 
substantially improved care continuum outcomes for those who became HIV-infected by age 
25. With a onetime screen at age 25, the proportion of HIV-infected youth diagnosed by age 
25 increased markedly compared to screening at other ages (77% versus 51–53%); the 
proportion with virologic suppression also increased (51% versus 34–36%). These 
projections depend on data about rates of linkage and retention in AYA after routine 
screening, which vary by setting. Linkage to care rates for AYA, for example, range from 
30% in Miami, FL to 92% in an emergency department in Bronx, NY (base case 76%) [13, 
33, 34]. The current practice scenario projected more optimistic virologic outcomes than 
were reported in a recent review or in the CDC Medical Monitoring Project (80% versus 
55% and 68% virologic suppression among those retained, respectively) [35, 36]. Our 
sensitivity analyses using lower rates of retention and suppression suggest that the benefits 
of an additional one-time screen are markedly attenuated if AYA are screened but 
subsequently do not remain in care and on ART. HIV-infected AYA have poorer outcomes 
compared to adults at every step of the HIV care continuum; interventions to support linkage 
and retention will therefore be critical to any HIV screening program for AYA [13, 37].
Third, any combination of current practice and an additional one-time screen among AYA 
without identified risk factors will detect only a small proportion of lifetime HIV infections, 
most of which occur after age 25. Even a perfect one-time screen at age 25 would detect 
only 13% of lifetime infections, and in our less optimistic base case scenario, this value was 
10%. Despite these modest contributions to HIV detection, a one-time screen at age 25 
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substantially improved clinical and cost-effectiveness outcomes compared to other one-time 
screening strategies. A screen at age 30, for example, led to lower CD4 cell count at 
diagnosis compared to a screen at age 25 because those infected at young ages experienced 
substantial CD4 cell count decline by age 30. Combinations of routine HIV screening 
strategies for AYA, along with repeat screening in high-risk youth at appropriate intervals, 
will be needed to curb the rising epidemic of HIV in US AYA [37].
There are several limitations to this model-based analysis. First, incidence inputs were 
estimated from rates of new diagnoses, because the true number of new infections is 
unknown [38]. To address this uncertainty, we adjusted these values by age-stratified CDC-
estimated proportions of infections that are undiagnosed, and then calibrated the model to 
NHSS data on CD4 cell count at diagnosis and total incidence rates. Second, current practice 
HIV screening inputs were derived from reported rates of HIV screening which likely do not 
capture barriers to HIV screening for all AYA (for example, the Youth Risk Behavior Survey 
only samples students in grades 9 through 12) [4]. Third, because of limited data in AYA, we 
assume HIV-related healthcare utilization was constant over the age group. We also excluded 
utility adjustments in the primary analysis. AYA aged 18–30 comprise only a small fraction 
of participants in HIV-specific health-related quality-of-life studies, and emerging data 
suggest that youth may attach different values to specific health states compared to adults 
[22]. When adult quality-of-life utility weights were applied to calculate ICERs with 
QALYs, all ICERs remained below $150,000/QALY; ICER thresholds ranging from 
$50,000–200,000/QALY have been recommended for use in the US [24]. We additionally 
used adult values when the rates reported in AYA seemed too extreme; for example, for test 
acceptance we used 80.0% instead of 95% reported among 13–21-year-olds, and varied this 
parameter in sensitivity analysis [34]. Fourth, we did not explore multiple generations of 
HIV transmission. The small (0.05–3.8%) proportion of primary HIV transmissions averted 
would likely make a one-time screen at all ages slightly more cost-effective; however, 
among AYA without identified risk behaviors, HIV prevalence by age 25 is so low that this 
impact is likely minimal.
Designed to assess routine one-time screening in AYA without identified HIV risk factors, 
this analysis did not examine the impact of repeat screening later in adulthood. Additionally, 
the results do not apply to AYA with identified risk factors. The peak HIV incidences 
(3.6/100PY and 7.2/100PY) examined in our sensitivity analyses mirrored that of higher risk 
populations (for example, Adolescent Trials Network study 110: 3.1/100PY; PROUD study 
9.0/100PY), but we lacked data to derive age-specific incidence rates for these groups [39, 
40]. Age-based, sexual identity- and orientation-based, racial/ethnic, and regional disparities 
have been described in both HIV screening and incidence [2, 4, 13, 33]. Risk factor 
assessment should be performed by health care practitioners and optimal screening strategies 
for known high-risk subgroups of AYA will be different than those presented in this analysis 
[41].
In summary, for AYA without identified HIV risk factors in the US, one-time routine HIV 
screening at age 25, shortly after the peak of HIV incidence, in addition to current screening 
practice, would improve clinical outcomes and be cost-effective compared to current US 
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screening practices alone. Focusing screening on AYA ages 18 or younger is a less efficient 
use of a one-time screen among AYA than screening at a later age.
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IMPLICATIONS AND CONTRIBUTION
This study found that for adolescents and young adults (AYA) without identified risk 
factors for HIV, a one-time routine HIV screen at age 25 would optimize clinical 
outcomes and be cost-effective. Focusing screening on AYA ages 18 or younger is a less 
efficient use of a one-time screen.
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Figure 1. 
Figure 1a. Proportion diagnosed by the HIV screening program for people HIV-infected at 
any age
This bar graph presents the proportion of people diagnosed by the HIV screening program 
for all HIV-infected people over their lifetime, regardless of the age of HIV infection. A one-
time screen at age 25 in addition to current practice screening will only detect 10.3% of 
infections, most of which occur after age 25.
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Figure 1b. Proportion diagnosed by the HIV screening program for all people HIV-infected 
before age 25 years
This bar graph presents proportion of people diagnosed by the HIV screening program for 
all HIV-infected people over their lifetime, limited to those who were infected before age 25. 
A one-time screen at age 25 in addition to current practice screening will detect 38.4% of 
infections.
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Figure 2. Proportions diagnosed and virologically suppressed, among people infected before age 
25 years
This bar graph presents cross-sectional virologic suppression at age 25 years and 11 months 
for AYA infected before age 25 years. Among people HIV-infected by age 25 years, 
proportion diagnosed with HIV and proportion virologically suppressed are shown cross-
sectionally at age 25 and 11 months. Compared to either current practice, or screens at ages 
15 or 18, a screen at age 25 substantially improved care continuum outcomes. A screen at 
age 30 is equivalent to current practice when considering the care continuum at age 25 years. 
HIV screening occurs in the first month of the year, while HIV care continuum outcomes are 
calculated in the eleventh month of the year.
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Figure 3. Sensitivity analyses: Screen at age 25 compared to current practice
Key parameters varied in model sensitivity analyses are shown on the left. Values in 
parentheses indicate the range examined. ICERs for the comparison of screen at 25 vs. 
current practice are shown on the horizontal axis, in 2013 USD/YLS. The range of ICERs 
for each varied parameter is indicated by the blue horizontal bars. Longer blue horizontal 
bars indicate parameters to which the model results were more sensitive. The solid, red 
vertical line indicates the ICER for screen at 25 vs. current practice using all base case 
parameters: $67,000/YLS. The dotted black vertical line indicates the “willingness–to-pay” 
threshold of <$100,000/year-of-life saved (YLS) [23, 24]. This figure provides a framework 
for when decisions are made on cost-effectiveness grounds – the value within the horizontal 
bar indicates when one would favor an additional one-time screen at 25 over current practice 
alone by this criterion. Bars extending to the far-right axis indicate scenarios in which screen 
at 25 results in an ICER of >$100,000/YLS in comparison to current practice. For the base 
case, we reported results according to cost-effectiveness analysis convention, with results 
shown in order of increasing costs and ICERs calculated comparing each strategy to the next 
most costly strategy after eliminating dominated strategies (Table 2). Here, we reported 
ICERs comparing the most effective strategy to current practice because of variation in the 
comparator strategies. Given the co-linearity of ICERs of one-time testing strategies 
(Appendix Figure A5), small changes in population life expectancy and population costs 
resulted in variation in comparator strategies when comparing the most effective strategy to 
the next best strategy.
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Table 1
Input parameters for a model of routine HIV screening in US adolescents and young adults
Population characteristics General US population Source
 Age (years) 12 Modeled population
 Male sex (%) 51.2 [10]
 HIV prevalence at age <12 (%) 0 Modeled population
Annual HIV incidence by age, rate/100,000PYa
 <13 years 0.6 [11, 12]
 15 1.8 [11, 12]
 18 22.9 [11, 12]
 21 59.1 [11, 12]
 24 71.3 [11, 12]
 25 54.3 [11, 12]
 26–30 46.3 [11, 12]
 31–35 38.3 [12]
 36–40 32.6 [12]
 41–45 32.1 [12]
 >45 8.6 [12]
Current HIV screening practice (annual probability)
 12–17 years 0.01 [4]
 18–34 0.16 [4]
 35–44 0.10 [4]
 45–64 0.06 [4]
 ≥65 0.02 [4]
Probability of linkage to care (%) 75.6 [13]
HIV screening program costs (USD 2013)c
 HIV screen 35.92 [14]
 Completed positive screen 72.23 [14, 15]
Antiretroviral therapy (range, 1st through 6th available regimen)d
 Efficacy (%) 93–81 [16–18]
 Cost/month (USD 2013) 2,170–3,570 [19, 20]
 Return to care (rate/100PY) 18.1 [21]
aComplete age-stratified incidence rates are reported in Table A1 and Figure A1.
b
Incidence estimates presented incorporate rates of new diagnoses in 2013 from the National HIV Surveillance System (NHSS) and undiagnosed 
incidence. (See appendix Table A1.)
c
HIV screen cost was derived from an average of reported costs with and without counseling at sexually transmitted infection clinics [14]. The cost 
of completing a positive screen was based on average reported costs at hospitals [15]. Costs include costs of reagents and controls, laboratory 
equipment costs, specimen collection, transport and process, quality control, counseling and personnel time at national wage and fringe labor rates.
dAntiretroviral efficacy is defined as the rate of suppression of HIV RNA <400 copies/mL at 48 weeks.
Additional references for inputs are noted in the appendix (Table A1).
PY: person-years; USD: US dollars
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